Bafna Pharmaceuticals (NSE:BAFNAPH) Land And Improvements: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BAFNAPH Bafna Pharmaceuticals Ltd NSE:BAFNAPH
57 GF Score
Price ₹308.00
GF Value ₹85.65
Valuation Significantly Overvalued
! 9 Warning Signs
View Full Analysis

What is Bafna Pharmaceuticals Land And Improvements?

Bafna Pharmaceuticals NSE:BAFNAPH -1.47% 57 Land And Improvements is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 57/100 and a GF Value™ of ₹85.65 (Significantly Overvalued). The stock has 9 warning signs investors should review.

Bafna Pharmaceuticals's land and improvements for the quarter that ended in Jun. 2026 was ₹0 Mil.

Bafna Pharmaceuticals's quarterly land and improvements increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹2 Mil) but then declined from Mar. 2026 (₹2 Mil) to Jun. 2026 (₹0 Mil).

Bafna Pharmaceuticals's annual land and improvements stayed the same from Mar. 2024 (₹2 Mil) to Mar. 2025 (₹2 Mil) and stayed the same from Mar. 2025 (₹2 Mil) to Mar. 2026 (₹2 Mil).

Bafna Pharmaceuticals Land And Improvements Historical Data

* Premium members only.

The historical data trend for Bafna Pharmaceuticals's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bafna Pharmaceuticals Land And Improvements Chart

Bafna Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Land And Improvements
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.93 1.93 1.93 1.93 1.93

Bafna Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Land And Improvements Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 1.93 0.00
NSE:BAFNAPH
57GF Score
Bafna Pharmaceuticals Ltd NSE:BAFNAPH
Land And Improvements is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bafna Pharmaceuticals Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Frequently Asked Questions Learn more about Land And Improvements →
What does a Land And Improvements of ₹0 Mil mean?
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Land And Improvements of ₹0 Mil as of Jun. 2026. Land and improvements records the total value of a company's land and improvements to it. View historical data on Bafna Pharmaceuticals and its competitors.
Is Bafna Pharmaceuticals' Land And Improvements too high?
Bafna Pharmaceuticals' current Land And Improvements is ₹0 Mil. Overall, Bafna Pharmaceuticals has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Land And Improvements compare to ZTS?
Bafna Pharmaceuticals' Land And Improvements of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Land And Improvements for a Drug Manufacturers company?
A good Land And Improvements depends on the Drug Manufacturers industry context. However, Land And Improvements should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Land And Improvements mean?
A high Land And Improvements can signal that a stock is expensive relative to its fundamentals. Land and improvements records the total value of a company's land and improvements to it. View historical data on Bafna Pharmaceuticals and its competitors. Bafna Pharmaceuticals's current Land And Improvements is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹85.65, compared to a current price of ₹308.00 — trading 259.6% above its estimated fair value. The current Land And Improvements is ₹0 Mil. Bafna Pharmaceuticals' overall GF Score™ is 57/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Land And Improvements calculated?
Land And Improvements is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Land And Improvements is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?

Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued. The current stock price of ₹308.00 is trading 259.6% above its estimated GF Value™ of ₹85.65. GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for NSE:BAFNAPH:

  • Land And Improvements: ₹0 Mil
  • GF Value™: ₹85.65 vs. price of ₹308.00 (259.6% above fair value)
  • GF Score™: 57/100 with 9 warning signs

No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bafna Pharmaceuticals Business Description

Other Exchanges 532989:India
Address Thambu Chetty Street, New No. 68, Old No. 299, Bafna Towers, Chennai, TN, IND, 600001
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
57GF Score

Get the complete analysis for NSE:BAFNAPH

Land And Improvements is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹308.00
Price
₹85.65
GF Value